Pravin S. Shirude

Pravin S. Shirude

Auto-generated profile, based on publicly available information

Pravin S. Shirude

Bristol Myers Squibb

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
MCMonalisa Chatterji
Monalisa Chatterji
RSRadha Shandil
Radha Shandil
MMM. R. Manjunatha
M. R. Manjunatha
SSSuresh Solapure
Suresh Solapure
VRVasanthi Ramachandran
Vasanthi Ramachandran
PSPravin S. Shirude
Pravin S. Shirude
New therapeutic strategies against multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis are urgently required to combat the global tuberculosis (TB) threat. Toward this end, we previously reported the identification of 1,4-azaindoles, a promising class of compounds with potent antitubercular activity through noncovalent inhibition of decaprenylphosphoryl-β- d -ribose 2′-epimerase (DprE1). Further, this series was optimized to improve its physicochemical properties and pharmacokinetics in mice. Here, we describe the short-listing of a potential clinical candidate, compound 2, that has potent cellular activity, drug-like properties, efficacy in mouse and rat chronic TB infection models, and minimal in vitro safety risks. We also demonstrate that the compounds, including compound 2, have no antagonistic activity with other anti-TB drugs. Moreover, compound 2 shows synergy with PA824 and TMC207 in vitro , and the synergy effect is translated in vivo with TMC207. The series is predicted to have a low clearance in humans, and the predicted human dose for compound 2 is ≤1 g/day. Altogether, our data suggest that a 1,4-azaindole (compound 2) is a promising candidate for the development of a novel anti-TB drug.

20 June 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PSPravin S. Shirude
Pravin S. Shirude
RSRadha K. Shandil
Radha K. Shandil
MMM. R. Manjunatha
M. R. Manjunatha
CSClaire Sadler
Claire Sadler
MPManoranjan Panda
Manoranjan Panda
MCMonalisa Chatterji
Monalisa Chatterji

23 September 2019 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MRManjunatha M. R
Manjunatha M. R
RSRadha K. Shandil
Radha K. Shandil
MPManoranjan Panda
Manoranjan Panda
CSClaire Sadler
Claire Sadler
AAAnisha Ambady
Anisha Ambady
PSPravin S. Shirude
Pravin S. Shirude

1 April 2004 in Tetrahedron Letters
Verified
Journal Article
Closed access
PSPravin S. Shirude
Pravin S. Shirude
VKVaijayanti A. Kumar
Vaijayanti A. Kumar
KGKrishna N. Ganesh
Krishna N. Ganesh

17 February 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PSPravin S. Shirude
Pravin S. Shirude
DCDaniel Cheney
Daniel Cheney
ACAmit K. Chattopadhyay
Amit K. Chattopadhyay
BSBalaji Seshadri
Balaji Seshadri
VBVishweshwaraiah Baligar
Vishweshwaraiah Baligar
NWNicholas R. Wurtz
Nicholas R. Wurtz

1 January 2014
Verified
Book Chapter
Closed access
PSPravin S. Shirude
Pravin S. Shirude
MCMonalisa Chatterji
Monalisa Chatterji
SNShridhar Narayanan
Shridhar Narayanan
PIPravin S. Iyer
Pravin S. Iyer